Cannabics Pharmaceuticals is dedicated to the development of advanced cannabinoid-based treatments and therapies.

Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on cannabinoid compounds.

The Company’s principal Technology is Cannabics SR, a technology for a long acting oil capsule that provides a safe, effective and reliable administration of cannabis.

Cannabics Pharmaceuticals Inc. is traded in the US OTC stock exchange, under the trade symbol: CNBX


June 6, 2016, Cannabics Pharmaceuticals has Filed a PCT Application, Covering a Novel Personalized Anti-Cancer Diagnostics System.

May 9, 2016, The DEA Could Reschedule Marijuana This Summer, And That Would Be A Game Changer For The Industry $CNBX $GWPH

April 2, 2016, Only A Few Public Companies Really Focus On Developing Medical Marijuana: Here's A List.

March 22, 2016, Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients.